Jump to content

Segesterone acetate/ethinylestradiol

Edit links
From Wikipedia, the free encyclopedia
(Redirected from Annovera)
Segesterone acetate/ethinylestradiol
Ethinylestradiol (top) and
segesterone acetate (bottom)
Combination of
Segesterone acetateProgestogen
EthinylestradiolEstrogen
Clinical data
Trade namesAnnovera
Other namesEE/SGA; EE/SA
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa604032
License data
Routes of
administration		Intravaginal
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin and ethinylestradiol, an estrogen.[1][2][3] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[1][4]

Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use.[5] Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed and can be stored at temperatures up to 30 degrees Celsius.[1]

The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018.[4][6]

See also

[edit]

References

[edit]
  1. ^ a b c d "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 7 August 2020. Retrieved 10 October 2020.
  2. ^ Nelson AL (October 2019). "Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method". Expert Review of Clinical Pharmacology. 12 (10): 953–963. doi:10.1080/17512433.2019.1669448. PMID 31526281. S2CID 202674265.
  3. ^ Lee AL (May 2020). "Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception". American Family Physician. 101 (10): 618–620. PMID 32412221.
  4. ^ a b "TherapeuticsMD Announces FDA Approval of Annovera (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control". TherapeuticsMD Inc (Press release). 10 August 2018. Retrieved 10 October 2020.
  5. ^ "FDA approves new vaginal ring for one year of birth control". U.S. Food and Drug Administration (FDS) (Press release). 10 August 2018. Retrieved 10 October 2020.
  6. ^ "Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol)". U.S. Food and Drug Administration (FDA). 10 September 2018. Retrieved 10 October 2020.
[edit]


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Segesterone_acetate/ethinylestradiol&oldid=1103042151"